Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress

REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended March 31, 2025, and provided an update on corporate progress. The company continues to make meaningful progress on its 2025 strategic priorities: Execute pivotal trials with daraxonrasib monotherapy in patients with previously treated metastatic ...